Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

18.55 +0.78 (+4.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
NovoCure Earnings Perspective: Return On Capital Employed
NovoCure (NASDAQ:NVCR) brought in sales totaling $140.87 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 416.63%, resulting in a loss of $24.01 million. 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: NovoCure Q2 Earnings
  NovoCure (NASDAQ:NVCR) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Novocure Reports Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
NovoCure: Q1 Earnings Insights
NovoCure (NASDAQ:NVCR) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Novocure's TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control
Novocure Ltd (NASDAQ: NVCR)  
Via Benzinga
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2022
Upgrades 
Via Benzinga
Novocure to Report Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
From Novocure
Via Business Wire
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022
Upgrades 
Via Benzinga
Novocure Reports First Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
From Novocure
Via Business Wire
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
From Novocure
Via Business Wire
Novocure to Report First Quarter 2022 Financial Results
From Novocure
Via Business Wire
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
From Novocure
Via Business Wire
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
Up On Bad News
Despite the plane crash in China, Boeing's stock is up today. 
Via Talk Markets
Lucky Day
Today Alleghany rose nearly 25% because it is being bought by Berkshire Hathaway, Warren Buffett's fund. 
Via Talk Markets
World Markets News For Friday
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
From Novocure
Via Business Wire
Novocure’s General Counsel Resigns After 10 Years of Service
From Novocure
Via Business Wire
Novocure Q4 Earnings Miss Street View, New Data Shows TTFields Initiates Downstream Anti-Tumor Response
A new study published in the Journal of Clinical Investigation (JCI) finds treatment with Novocure Ltd's (NASDAQ: NVCR) Tumor Treating Fields (TTFields) mediated... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.